Pfizer Lung Cancer Trial Sends Warning on Oncology Pivot
Can Pfizer’s lung cancer setback stay contained to one trial, or is it an early warning for its broader oncology turnaround?
Can Pfizer’s lung cancer setback stay contained to one trial, or is it an early warning for its broader oncology turnaround?
Can Pfizer convince Wall Street this CFO change is about continuity, not a deeper warning on execution and growth?
Can the Pfizer Lyme vaccine’s >70% efficacy data revive sentiment around PFE just as investors write off its post-COVID growth story?